2289.Hk
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products and related medical research.
Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products and related medical research.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products and related medical research.
The company maintains a market capitalization of 628.56 million CNY and a price-to-earnings ratio of 13.58, indicating a moderate valuation relative to its earnings. Its price-to-book ratio of 1.02 suggests that the market values the company's equity in line with its book value. The company's liquidity position is characterized by a current ratio of 1.09, which is slightly above 1, indicating a modest ability to meet short-term obligations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.
In terms of profitability, the company's return on equity (ROE) is 7.51%, which is relatively low compared to industry benchmarks. The return on assets (ROA) is 1.17%, further indicating that the company is not efficiently utilizing its assets to generate profits. The gross profit margin is 7.53%, and the operating margin is 1.55%, both of which are below the industry median, suggesting that the company is facing challenges in maintaining profitability.
The company's revenue is primarily concentrated in a single geographic region, with no disclosed segment breakdown. This lack of diversification increases the company's exposure to regional economic and regulatory risks. The company's revenue for the latest period was 4.38 billion CNY, with a gross profit of 330.33 million CNY and an operating income of 68.10 million CNY.
The company's growth trajectory is modest, with a revenue of 4.38 billion CNY for the latest period. The company's net income was 46.27 million CNY, and its earnings per share (EPS) were 0.41 CNY. The company's debt-to-equity ratio is 1.94, indicating a high level of leverage, which could constrain its ability to invest in growth opportunities.
The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could lead to liquidity constraints. The company's debt-to-equity ratio of 1.94 suggests that it is highly leveraged, which could increase its financial risk. The company's dilution risk is low, as there is no indication of significant share issuance or dilution potential.
Recent events and filings indicate that the company has not disclosed any significant new developments or strategic initiatives. The company's latest actual EPS was 0.41 CNY, and its latest actual revenue was 4.096 billion CNY. The company's financial performance has been stable, but there are no indications of significant growth or innovation in the near term.
- The company has a moderate valuation with a price-to-earnings ratio of 13.58 and a price-to-book ratio of 1.02.
- The company's profitability metrics, including ROE and ROA, are below industry medians, indicating inefficiencies in asset utilization and equity returns.
- The company's revenue is concentrated in a single geographic region, increasing its exposure to regional economic and regulatory risks.
- The company's debt-to-equity ratio of 1.94 suggests a high level of leverage, which could constrain its ability to invest in growth opportunities.
- The company's liquidity position is modest, with a current ratio of 1.09 and a negative net cash position after subtracting total debt.
- The company's recent financial performance has been stable, but there are no indications of significant growth or innovation in the near term.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 2289.HK Market data — financials · 2026-05-26
- Charmacy Pharmaceutical Co Ltd Market data — analyst estimates · 2026-05-26